HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
10 May 2023 - 6:30PM
HUTCHMED (China) Limited (“HUTCHMED” or the “Company”)
(Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Solange
Peters is appointed as an Independent Non-executive Director,
member of the Technical Committee and member of the Audit Committee
of the Company with effect from the conclusion of the annual
general meeting of the Company to be held on May 12, 2023.
Professor Peters is a renowned scientist and educator who possesses
expertise and extensive experience in oncology and immunology. The
Board of HUTCHMED is of the view that Professor Peters will make
significant contributions to the Company.
Mr Simon To, Chairman of HUTCHMED said “On
behalf of the Board, I would like to extend a warm welcome to
Professor Peters to the Company. We believe that her expertise in
biopharmaceutical research in oncology and immunology would be of
immense value to the Company and she would be instrumental in
assisting the Company in achieving its goals.”
Professor Peters, aged 50, is the chair of
medical oncology and thoracic malignancies in the Department of
Oncology at the University Hospital of Lausanne in Lausanne,
Switzerland. After completing her clinical education in medical
oncology and molecular biology in Switzerland and Italy, she
specialized in thoracic tumors, lung cancer, and pleural tumors.
Professor Peters was the youngest president of the European Society
for Medical Oncology (ESMO) for an extended period of three years
from 2020 to 2022, and she is active in the educational programmes
of ESMO, where she created the Women for Oncology Committee.
Professor Peters was also a member of the board of directors of the
International Association for the Study of Lung Cancer (IASLC) from
2013 to 2017.
Professor Peters is currently in charge of
teaching and patient care in thoracic malignancies at Lausanne
University, where she is building a translational programme in
collaboration with the Swiss Federal Institute of Technology and
the Ludwig Institute. Her main fields of interest are new biomarker
discovery and validation in preclinical and clinical settings,
multimodality strategies for locally advanced non-small cell lung
cancer (NSCLC), as well as cancer immunotherapy. Her current
research projects are mainly focused on innovative immunotherapy
combinations and new immuno-modulating treatments across thoracic
malignancies. She acts as the local principal investigator (PI) for
lung trials opened at Lausanne Cancer Centre and is a co-PI of
several other trials.
Professor Peters acts as the scientific
committee chair and foundation council member of the ETOP IBCSG
Partners Foundation. She was recently nominated as the strategic
advisory board president of the Paris Saclay Cancer Cluster and is
part of the board of directors of the Swiss National Cancer League.
She is also the president of International Cancer Foundation.
Professor Peters is also an independent director of Galenica AG,
which is listed on the SIX Swiss Exchange.
Professor Peters has authored more than 500
peer-reviewed manuscripts and book chapters, acts as Associate
Editor of the Annals of Oncology, Deputy Editor of Lung Cancer, and
serves on the editorial board of several other oncology journals.
She was the deputy editor of the Journal of Thoracic Oncology for
ten years. She received both her doctorate in medicine and PhD from
the University Hospital of Lausanne.
Save for the appointments listed above,
Professor Peters has held no other directorships or partnerships
during the period of five years prior to her appointment as a
director of HUTCHMED. She does not have any relationship with any
Directors, senior management or substantial or controlling
shareholders of HUTCHMED. Professor Peters does not have any
interest in the ordinary shares of HUTCHMED within the meaning of
Part XV of the Securities and Futures Ordinance (Cap.571 of the
Laws of Hong Kong). The initial term of the appointment of
Professor Peters as an Independent Non-executive Director of the
Company shall end at the next general meeting of the Company,
subject to retirement in accordance with the Articles of
Association of the Company and applicable legal and regulatory
requirements. The initial term shall be automatically renewed for
successive 12-month periods, unless she is not re-elected at the
next general meeting or her appointment is otherwise terminated
earlier by either party in writing. The director’s fees of
Professor Peters as an Independent Non-executive Director, member
of the Technical Committee and member of the Audit Committee of the
Company under her appointment letter are US$76,000, US$8,000 and
US$13,500 per annum respectively. Such fees are subject to review
from time to time and proration for any incomplete year of
service.
Save for the information disclosed above, there
is no other information in relation to Professor Peters that is
required to be disclosed pursuant to Rule 17 and Schedule 2(g) of
the AІM Rules for Companies or Rule 13.51(2) of the HK Listing
Rules and there are no other matters concerning the appointment of
Professor Peters that are required to be brought to the attention
of the shareholders of HUTCHMED.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an
innovative, commercial-stage, biopharmaceutical company. It is
committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect HUTCHMED’s current expectations
regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among
other things, the risk that current or future appointees to
HUTCHMED’s board of directors are not effective in their respective
positions, the difficulty in locating and recruiting suitable
candidates for its board of directors and the management
difficulties which may arise from changes in HUTCHMED’s board of
directors. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. For further discussion of these
and other risks, see HUTCHMED’s filings with the U.S. Securities
and Exchange Commission, on AІM and with The Stock Exchange of Hong
Kong Limited. HUTCHMED undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 306-4490 |
|
|
Media Enquiries |
|
Americas – Brad Miles, Solebury Strategic
Communications |
+1 (917) 570 7340 (Mobile) /
bmiles@soleburystrat.com |
Europe – Ben Atwell / Alex Shaw,
FTI Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com |
Asia – Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure
Gordon |
+44 (20) 7886 2500 |
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Apr 2023 to Apr 2024